Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Su X, Colditz GA, Collins LC, Baer HJ, Sampson LA, Willett WC, Berkey CS, Schnitt SJ, Connolly JL, Rosner BA, Tamimi RM (2012) Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease. Breast Cancer Res Treat
2.
Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869–878PubMedCrossRef
3.
Prieto-Alhambra D, Servitja S, Javaid MK, Garrigos L, Arden NK, Cooper C, Albanell J, Tusquets I, Diez-Perez A, Nogues X (2012) Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study. Breast Cancer Res Treat
4.
Rohan TE, Negassa A, Chlebowski RT, Ceria-Ulep CD, Cochrane BB, Lane DS, Ginsberg M, Wassertheil-Smoller S, Page DL (2009) A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat 116(2):339–350PubMedCrossRef
5.
Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, Wolff RK, Giuliano AR (2012) Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat 132(2):683–691PubMedCrossRef
6.
Singh S, Cuzick J, Mesher D, Richmond B, Howell A (2012) Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat 132(2):625–629PubMedCrossRef
7.
Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, Aiello Bowles EJ, Stanczyk FZ, Sisney GS, Skinner HG (2012) The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Res Treat 131(1):255–265PubMedCrossRef
8.
Wang C, Baumgartner RN, Yang D, Slattery ML, Murtaugh MA, Byers T, Hines LM, Giuliano AR, Baumgartner KB (2009) No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women. Breast Cancer Res Treat 114(1):137–145PubMedCrossRef
9.
Grant WB, Boucher BJ (2011) Low vitamin D status likely contributes to the link between periodontal disease and breast cancer. Breast Cancer Res Treat 128(3):907–908PubMedCrossRef
10.
Marcinowska-Suchowierska E, Walicka M, Talalaj M, Horst-Sikorska W, Ignaszak-Szczepaniak M, Sewerynek E (2010) Vitamin D supplementation in adults - guidelines. Endokrynol Pol 61(6):723–729PubMed
11.
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ (2012) 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat
12.
Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 121(2):469–477PubMedCrossRef
Metadata
Title
Comments on adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease
Authors
Chun Zhang
Guo-Qiang Lv
Jian-Ping Li
Ping Zhou
Publication date
01-08-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2153-y

Other articles of this Issue 3/2012

Breast Cancer Research and Treatment 3/2012 Go to the issue

Clinical trial

The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study

Epidemiology

Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management

Preclinical study

Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors

Preclinical Study

Non-invasive quantification of tumor vascular architecture during docetaxel-chemotherapy

Epidemiology

Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution

Epidemiology

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits